Irbesartan Stada

Irbesartan, the active ingredient in Irbesartan Stada, is a Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It treats elevated blood pressure and helps protect kidney function in patients with diabetic kidney disease. GNH USA supplies Irbesartan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan belongs to the angiotensin II receptor blocker class and is used to manage conditions related to the renin‑angiotensin system. - Hypertension: lowers elevated blood pressure in adult patients. - Diabetic nephropathy: slows the progression of kidney disease in individuals with type 2 diabetes. - Renal protection: reduces proteinuria associated with diabetic kidney disease, helping preserve renal function.

Common side effects are generally mild and reversible.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pressure sensation. - Fatigue: feeling unusually tired or weak. - Upper respiratory tract infection: nasopharyngitis symptoms. - Diarrhea: loose stools occurring intermittently. - Cough: dry, non‑productive cough.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway requiring emergency care. - Hyperkalaemia: elevated blood potassium that can affect heart rhythm. - Acute renal failure: sudden decline in kidney function. - Hepatic injury: signs of liver dysfunction such as jaundice. - Severe hypotension: markedly low blood pressure causing faintness. - Anaphylactic reaction: rare systemic allergic response.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant laboratory parameters. - Renal function: assess serum creatinine and eGFR before and during treatment. - Serum potassium: monitor potassium levels, especially when combined with potassium‑sparing agents. - Volume depletion: use caution in patients with dehydration or diuretic therapy. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy: avoid use in the second and third trimesters due to fetal risk. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan may interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use can increase renal risk. - Dual ARB/ACE‑inhibitor therapy: heightened risk of hyperkalaemia and renal impairment. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous potassium elevation. - Lithium: concomitant use can raise lithium concentrations. - Strong CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan exposure.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: additive blood‑pressure effect, monitor electrolytes. - NSAIDs: may reduce antihypertensive efficacy and affect renal function. - CYP3A4 inducers (e.g., rifampin): may lower irbesartan levels. - Antihypertensive agents (e.g., beta‑blockers): monitor for excessive hypotension. - Diuretics causing volume loss: watch for orthostatic symptoms.